This systematic review examines the strengths and limitations of current biomarkers used in diagnosing and monitoring mitochondrial diseases (MDs), emphasizing the need for more specific, reliable markers. While traditional markers like lactate and organic acids remain widely used, newer options like circulating cell-free mitochondrial DNA show promise but require further
